Tectonic Therapeutic, Inc. (TECX): who owns it and who trades it
As of Nov 16, 2026, TECX insiders reported 11 open-market sales worth $651K and 2 purchases worth $182K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marcella K. Ruddy (Chief Medical Officer), with $363K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tectonic Therapeutic
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TECX
124 funds and institutions reported TECX shares worth $481M at the end of Q2 2026, about 74% of the company. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) 74%Everyone else 26%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 2.83M | 15.00% | $97.3M | +0% |
| TCG Crossover Management, LLC | 1.20M | 6.39% | $41.4M | No change |
| Aberdeen Group plc | 1.14M | 6.05% | $39.3M | No change |
| BlackRock, Inc. | 862,592 | 4.57% | $29.7M | +0% |
| First Light Asset Management, LLC | 800,726 | 4.24% | $27.5M | +24% |
| Baker Bros. Advisors LP | 607,788 | 3.22% | $20.9M | No change |
| 5AM Venture Management, LLC | 606,660 | 3.22% | $20.9M | No change |
| Braidwell LP | 596,900 | 3.16% | $20.5M | -30% |
| Vanguard Capital Management LLC | 488,805 | 2.59% | $16.8M | +3% |
| Vestal Point Capital, LP | 425,000 | 2.25% | $14.6M | +30% |
| Bollard Group LLC | 302,953 | 1.61% | $10.4M | No change |
| Kennedy Capital Management LLC | 282,202 | 1.50% | $9.7M | -2% |
| Geode Capital Management, LLC | 270,461 | 1.43% | $9.3M | +1% |
| Orbimed Advisors LLC | 226,600 | 1.20% | $7.8M | No change |
| State Street Corp | 219,908 | 1.17% | $7.6M | +3% |
| Ikarian Capital, LLC | 205,837 | 1.09% | $7.1M | +31% |
| D. E. Shaw & Co., Inc. | 186,550 | 0.99% | $6.4M | +61% |
| Marshall Wace, LLP | 172,101 | 0.91% | $5.9M | -25% |
| Millennium Management LLC | 165,525 | 0.88% | $5.7M | +184% |
| Squarepoint Ops LLC | 145,028 | 0.77% | $5M | -12% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TECX insiders reported $182K of open-market purchases and $651K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 536 | $23.04 | $12.3K | Form 4 |
| Aug 25, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 43 | $36.52 | $1.6K | Form 4 |
| Aug 12, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 43 | $35.00 | $1.5K | Form 4 |
| Jun 30, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 172 | $35.00 | $6K | Form 4 |
| May 4, 2026 | Marcella K. Ruddy | Chief Medical Officer | Sale plan | 1,065 | $30.00 | $31.9K | Form 4 |
| Apr 1, 2026 | Marcella K. Ruddy | Chief Medical Officer | Sale plan | 1,000 | $31.05 | $31.1K | Form 4 |
| Mar 6, 2026 | Marcella K. Ruddy | Chief Medical Officer | Sale plan | 10,000 | $30.00 | $300K | Form 4 |
| Mar 6, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 215 | $35.00 | $7.5K | Form 4 |
| Mar 6, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 6,047 | $30.00 | $181K | Form 4 |
| Mar 4, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 1,650 | $25.00 | $41.2K | Form 4 |
| Mar 3, 2026 | Peter McNamara | Chief Scientific Officer | Sale plan | 1,649 | $22.06 | $36.4K | Form 4 |
| Feb 11, 2026 | Alise Reicin | CEO | Purchase | 2,500 | $21.10 | $52.8K | Form 4 |
| Feb 10, 2026 | Daniel Lochner | CFO | Purchase | 6,000 | $21.61 | $130K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Marcella K. Ruddy | Chief Medical Officer | – | $363K | May 4, 2026 |
| Peter McNamara | Chief Scientific Officer | – | $288K | Sep 30, 2026 |
| Daniel Lochner | Chief Financial Officer | $130K | – | Feb 10, 2026 |
| Alise Reicin | Chief Executive Officer, Director | $52.8K | – | Feb 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TECX short interest
High short interest. 11.9% of TECX shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.38M TECX shares were sold short, 11.9% of the shares outstanding, up 6.8% from the report before. At the average daily volume of 173,921 shares, buying them all back would take about 13.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.38M | 11.91% | +7% | 173,921 | 13.7 |
| Oct 15, 2026 | 2.22M | 11.38% | +0% | 210,279 | 10.6 |
| Sep 30, 2026 | 2.22M | 11.37% | +0% | 275,508 | 8.1 |
| Sep 15, 2026 | 2.22M | 11.35% | +14% | 170,592 | 13.0 |
| Aug 31, 2026 | 1.94M | 9.94% | +12% | 255,869 | 7.6 |
| Aug 14, 2026 | 1.73M | 8.83% | -2% | 204,884 | 8.4 |
| Jul 31, 2026 | 1.76M | 9.03% | -9% | 164,029 | 10.8 |
| Jul 15, 2026 | 1.94M | 10.26% | -9% | 255,529 | 7.6 |
| Jun 30, 2026 | 2.14M | 11.32% | -1% | 149,301 | 14.3 |
| Jun 15, 2026 | 2.15M | 11.41% | -8% | 129,301 | 16.6 |
| May 29, 2026 | 2.34M | 12.41% | -10% | 221,016 | 10.6 |
| May 15, 2026 | 2.61M | 13.84% | +6% | 255,380 | 10.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tectonic Therapeutic company events
Tectonic Therapeutic filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026DealCompleted a purchase or sale of a business or assets. Filing
- Sep 29, 2026AnnouncementTectonic Therapeutic, Inc. issued a press release titled “Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)”. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 10, 2026AnnouncementThe Company issued a press release titled “Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 23, 2026LeadershipThe Board of Directors of Tectonic Therapeutic, Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jessica Chutter as a member of the Board and as a member of the Audit Committee of the Board, effective as of the date of the Company’s 2026 annual… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 24, 2026LeadershipThe Board of Directors of Tectonic Therapeutic, Inc., upon recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from six directors to seven directors effective as of the Effective Date (as defined below) and appointed… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold TECX
3 of the 50 well-known investors we track reported holding TECX in their latest 13F filing. The largest position is Ken Griffin's, worth $4.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 193,039 | $4.5M | 0.0% | +114% |
| Israel Englander · Millennium Management | Q3 2026 | 126,963 | $3M | 0.0% | -23% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 19,122 | $445K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TECX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 29, 2026 | Aberdeen Group plc | 13G/A | 2.5% |
| Oct 29, 2026 | Aberdeen Group plc | 13G/A | 2.5% |
Questions about Tectonic Therapeutic, Inc. (TECX) stock
Who owns the most TECX stock?
The largest reported owner of Tectonic Therapeutic, Inc. (TECX) is FMR LLC (Fidelity), with 15.0% of the company. In total, 124 funds and institutions reported holding TECX at the end of Q2 2026, together about 74% of the shares. See the largest owners.
Are TECX insiders buying or selling?
In the last 12 months, TECX insiders reported 2 open-market purchases worth $182K and 11 sales worth $651K. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in TECX?
As of Oct 30, 2026, 2.38M TECX shares were sold short, 11.9% of the shares outstanding, up 6.8% from the report before. At the average daily volume of 173,921 shares, buying them all back would take about 13.7 trading days (days to cover). See the history.
Which famous investors hold TECX?
3 of the 50 well-known investors we track reported TECX in their latest 13F filing, including Ken Griffin, Israel Englander, Ken Fisher. The largest position is worth $4.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.